Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

January 31, 2013

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine

Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.

DRUG

oxaliplatin

Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.

PROCEDURE

Radiation

The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.

Trial Locations (4)

21231

Johns Hopkins University, Baltimore

43210

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Johns Hopkins University

OTHER

collaborator

Princess Margaret Hospital, Canada

OTHER

collaborator

Ohio State University

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT00456599 - Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter